Cingulate (NASDAQ:CING) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cingulate (NASDAQ:CING) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Roth Capital set a $9.00 target price on shares of Cingulate and gave the company a “buy” rating in a research note on Sunday, August 23rd. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Cingulate in a research report on Tuesday, May 26th. Finally, Ascendiant Capital Markets dropped their price target on shares of Cingulate from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cingulate presently has an average rating of “Moderate Buy” and an average price target of $27.00.

Cingulate Trading Down 2.8%

CING opened at $5.17 on Friday. The stock’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $5.52. The stock has a market cap of $75.17 million, a PE ratio of -1.44 and a beta of -0.90. Cingulate has a 1 year low of $3.16 and a 1 year high of $11.89.

Cingulate (NASDAQ:CING) last issued its earnings results on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.18. Equities analysts forecast that Cingulate will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Cingulate

A number of large investors have recently bought and sold shares of CING. Bank of America Corp DE lifted its holdings in shares of Cingulate by 283.1% during the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after acquiring an additional 5,543 shares during the period. Soltis Investment Advisors LLC acquired a new stake in shares of Cingulate in the 4th quarter valued at $43,000. XTX Topco Ltd acquired a new stake in shares of Cingulate in the 2nd quarter valued at $45,000. Quadrature Capital Ltd bought a new stake in shares of Cingulate in the 4th quarter worth about $66,000. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Cingulate in the 1st quarter worth about $116,000. 41.31% of the stock is currently owned by institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.